

United States Facent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
WWW.100pld.gov

			• •		
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/992,936	11/05/2001	Robert F. Kaiko	200.1102CP2	9880	
23280 7.	590 02/04/2002				
DAVIDSON, DAVIDSON & KAPPEL, LLC			EXAM	EXAMINER	
485 SEVENTE NEW YORK, 1	I AVENUE, 14TH FLO NY 10018	OOR	WARE, TODD		
			ART UNIT	PAPER NUMBER	
4			1615	9	
	·	<u>₩</u>	DATE MAILED: 02/04/2002)	

Please find below and/or attached an Office communication concerning this application or proceeding.

4)	• •		Application No.	Applicant(s)			
Examiner -7h. MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply A SHORTENICE OF THIS COMMUNICATION. - Exeminous of time may be available unable the production of the cover sheet with the correspondence address THE MAILING DATE OF THIS COMMUNICATION. - Exeminous of time may be available unable the production of the cover sheet with the correspondence and the cover sheet with the correspondence and the cover sheet with the production of the cover sheet with the correspondence and the cover sheet the correspondence of the cover sheet the cover sheet the cover sheet the cover sheet and the cover sheet sheet the cover sheet the cover sheet	Office Action Summary		09/992.936	KAIKO ET AL.			
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. Edenticine Cut time may be available under the provisions of 3 CPR 1.13(a), in no event, however, may a reply be timely filled after \$1X, (6) MONTHS from the mailing date of this communication. Edenticine Cut time may be available under the provisions of 3 CPR 1.13(a), in no event, however, may a reply be timely filled after \$1X, (6) MONTHS from the mailing date of this communication. If the provision of the provision of the provision of the communication of the provision of the communication. Palable to reply within the soft or extended princip for reply will, by distulut, cause the application to become ABMODISED (05 U.S.C. \$ 133). Any reply receive by the Office shad no the maining date of the communication. Palable to reply within the soft or extended princip for reply will, by distulut, cause the application to become ABMODISED (05 U.S.C. \$ 133). Any reply receive by the Office shad no the maining date of the communication. Palable to reply within the soft or extended princip for reply will, by distulut, cause the application to become ABMODISED (05 U.S.C. \$ 133). Any reply receive by the Office shad no reply and the maining date of the communication. Palable to reply within the action of the time and the provision of the communication of the communication of the communication of the provision of Claims (a) — If the provision of Claims (b) — If the above claim(s) — is/are allowed. Claim(s)			·				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. after 8X (6) MONTHS from the mailing table of libs communication. If the period for poly specified above, the maximum isolatory practive all apply within the distulery minimum of thiny (30) days will be considered timely. If the period for poly specified above, the maximum isolatory practive all apply to the distulery minimum of thiny (30) days will be considered timely. If the period for poly specified above, the maximum isolatory practive all apply to the distulery minimum of thiny (30) days will be considered timely. If the period for poly is specified above, the maximum isolatory practive all apply to the distulence of the communication. Provided the maximum isolatory and the provided and the provided and the communication, wen if timely fleet, may reduce any seasoned patient term asplication is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) ○ Claim(s) 1.3.6-32 and 34-36 is/are pending in the application. 4a) Of the above claim(s) is/are allowed. 5) □ Claim(s) is/are allowed. 5) □ Claim(s) as-32 and 34-36 is/are rejected. 7) □ The drawing(s) filed on is/are allowed. 4pplication Papers 9) □ The specification is objected to by the Examiner. Application Papers 9) □ The proposed drawing correction filed on is/are: allowed. 10 □ The drawing(s) filed on is/are: allowed. 11 □ The proposed drawing correction filed on is/are: allowed. 12 □ Craim(s) as-32 and as-32 is/are rejected. 13 □ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). 2a) □ All b) □ Some * c) □ None of: 14 □ Acknowledgment is			Todd D Ware	1615			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. Eatheristics of them by the switched before the communication. If the period for regity specifies above is less than thirty (30) days, a reply value in the statutory minimum of thirty (30) days, as well be considered thind). If the period for regity specifies above is less than thirty (30) days, a reply value in the statutory minimum of thirty (30) days, as well be considered thind). If the period for regity specifies above is less than thirty (30) days, a reply value in the statutory minimum of the regity is all days of the considered thind). If the period for regity specifies above is less than thirty (30) days, a reply value in the statutory minimum of the scanner of the statutory minimum of the scanner of			ears on the cover sheet with the c	orrespondenc address			
THE MAILING DATE OF THIS COMMUNICATION. - Edeteniors of time map be available under the provisions of 3 CPR 1.13(6). In no event, however, may a roply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period from the part of the communication of the communication of the part of the communication of the part of		• •	(IO OFT TO EVOIDE OMONITU	CONTROLL			
1) Responsive to communication(s) filed on 05 November 2001. 2a)	THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1.3.6-32 and 34-36 is/are pending in the application. 4a) Of the above claim(s) is/are pending in the application. 4a) Of the above claim(s) is/are pending in the application. 5) Claim(s) 1.3.6-32 and 34-36 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) is/are objected to. 8) Claim(s) is/are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or bi objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved by the Examiner. If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. §§ 119 and 120 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received in Application No. application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies on treceived. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 120 and/or 121. Attachment(s)		Responsive to communication(s) filed on 05 N	lovember 2001 .	•			
3 Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4 Claim(s) 1,3,6-32 and 34-36 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5 Claim(s) is/are allowed. 6 Claim(s) is/are allowed. 6 Claim(s) is/are objected to. 8 Claim(s) are subject to restriction and/or election requirement. Application Papers 9 The specification is objected to by the Examiner. 10 The drawing(s) filed on is/are: a accepted or b objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11 The proposed drawing correction filed on is: a) approved b the Examiner. If approved, corrected drawings are required in reply to this Office action. 12 The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. §§ 119 and 120 13	·	· · · · <u> </u>					
4) Claim(s) 1.3.6-32 and 34-36 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) is/are allowed. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 and 120 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1 Certified copies of the priority documents have been received in Application No 3 Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 120 and/or 121. Attachment(s)	3)	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
4a) Of the above claim(s) is/are withdrawn from consideration. 5) □ Claim(s) is/are allowed. 6) ☒ Claim(s) is/are allowed. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/or election requirement. Application Papers 9) □ The specification is objected to by the Examiner. 10) □ The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) □ The proposed drawing correction filed on is: a) □ approved b) □ disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action. 12) □ The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. §§ 119 and 120 13) □ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) □ All b) □ Some * c) □ None of: 1. □ Certified copies of the priority documents have been received. 2. □ Certified copies of the priority documents have been received in Application No 3. □ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a) □ The translation of the foreign language provisional application has been received. 15) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s) 10 ☒ Notice of References Cited (PTO-892) 21 ☐ Notice of Informal Patent Application (PTO-152)	Disposition of Claims						
5) □ Claim(s) is/are allowed. 6) ☒ Claim(s) is/are objected to. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/or election requirement. Application Papers 9) □ The specification is objected to by the Examiner. 10) □ The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) □ The proposed drawing correction filed on is: a) □ approved b) □ disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action. 12) □ The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. §§ 119 and 120 13) □ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) □ All b) □ Some * c) □ None of: 1. □ Certified copies of the priority documents have been received. 2. □ Certified copies of the priority documents have been received in Application No 3. □ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a) □ The translation of the foreign language provisional application has been received. 15) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s) 10 ☒ Notice of References Cited (PTO-892) 21 ◯ Notice of Oratsperson's Patent Drawing Review (PTO-948) 50 ☐ Notice of Informal Patent Application (PTO-152)	4) 🖾	4)⊠ Claim(s) <u>1,3,6-32 and 34-36</u> is/are pending in the application.					
6) Claim(s) 1,3,6-32 and 34-36 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 and 120 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 120 and/or 121. Attachment(s) 10 Interview Summary (PTO-413) Paper No(s). 1 Inte	4a) Of the above claim(s) is/are withdrawn from consideration.						
7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/or election requirement. Application Papers 9) □ The specification is objected to by the Examiner. 10) □ The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.	5) 🗌	5) Claim(s) is/are allowed.					
8	6)⊠ Claim(s) <u>1,3,6-32 and 34-36</u> is/are rejected.						
Application Papers 9)	7)	Claim(s) is/are objected to.					
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. §§ 119 and 120 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some collar collar for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). 2. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s) 1) Notice of References Cited (PTO-992) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 5 Notice of Informal Patent Application (PTO-152)	8) 🗌	Claim(s) are subject to restriction and/or	election requirement.				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. §§ 119 and 120 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s) 1) Notice of References Cited (PTO-892) 3) Notice of Informal Patent Application (PTO-152)	Application	on Papers					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. §§ 119 and 120 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) Notice of Informal Patent Application (PTO-152)	, —	•					
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. §§ 119 and 120 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 10 Interview Summary (PTO-413) Paper No(s)	10) 🔲 🗆						
If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. §§ 119 and 120 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some colonge of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) Notice of Informal Patent Application (PTO-152)							
12) ☐ The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. §§ 119 and 120 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a) ☐ The translation of the foreign language provisional application has been received. 15) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s) 1) ☒ Notice of References Cited (PTO-892) 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) Notice of Informal Patent Application (PTO-152)	,— · · ·						
Priority under 35 U.S.C. §§ 119 and 120 13)							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a)	, _ , , , , , , , , , , , , , , , , , ,						
a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)							
1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 1 Interview Summary (PTO-413) Paper No(s)							
2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s) 1) Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) 1) Interview Summary (PTO-413) Paper No(s) Notice of Informal Patent Application (PTO-152)	,_ ,_ ,_						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 1 Interview Summary (PTO-413) Paper No(s). 5) Notice of Informal Patent Application (PTO-152)							
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s) 1) Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) 1) Interview Summary (PTO-413) Paper No(s). Notice of Informal Patent Application (PTO-152)							
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 4) Interview Summary (PTO-413) Paper No(s) 5) Notice of Informal Patent Application (PTO-152)	application from the International Bureau (PCT Rule 17.2(a)).						
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 4) Interview Summary (PTO-413) Paper No(s) 5) Notice of Informal Patent Application (PTO-152)	14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 4) Interview Summary (PTO-413) Paper No(s) 5) Notice of Informal Patent Application (PTO-152)	, _						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) Notice of Informal Patent Application (PTO-152)	Attachment(s)						
	2) Notice	e of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal				

Art Unit: 1615

DETAILED ACTION

Receipt of preliminary amendment filed 11-5-01 is acknowledged. Claims 2, 4-5, and 33 have been canceled and claims 1, 12-18, and 32 have been amended as requested. Claims 1, 3, 6-32, and 34-36 are pending.

Claim Rejections - 35 USC § 103

- 1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 2. Claims 1, 3, 6, 8-10, 12-18, 21-26, 32, 34, and 36 are rejected under 35 U.S.C. 103(a) as being unpatentable over Crain et al (5,512,578; hereafter '578) in view of Hynes (EP 0 193 355; hereafter '355) or Crain et al (5,512,578; hereafter '578) in view of Raffa et al (5,336,691; hereafter '691) or Crain et al (5,512,578; hereafter '578) in view of Dudzinski (4,237,140; hereafter '140).

The instant claims are directed toward combination opioid agonist/antagonist/acetaminophen oral formulations and a method for treating pain with the combination opioid agonist/antagonist/acetaminophen oral formulations.

'578 teaches oral compositions comprising opioid agonists and opioid antagonists that may be used for treating opioid abuse. '578 also teaches a method

Art Unit: 1615

treating pain with the disclosed composition. '578 does not teach the inclusion of nonnarcotic analgesics in the disclosed formulation.

'355, '691, and '140 all teach inclusion of non-narcotic analgesics, such as acetaminophen in narcotic formulations. These references show that the interaction between the active agents is superadditive or synergistic.

Accordingly, it would have been obvious to one skilled in the art at the time of the invention to include non-narcotic analgesics in the formulation of '578 in an effort to provide enhanced analgesia by means of producing analgesia though non-opioid antinociceptive pathways. Furthermore, since the interactions are synergistic, it would have been obvious to one skilled in the art at the time of the invention to use doses that would otherwise be subtherapeutic if given alone with the motivation of maintaining low instance of side effects while maintaining an analgesic dose.

3. Claims 1, 3, 6, 8-10, 12-18, 21-26, 32, 34, and 36 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gordon et al (4,457,933; hereafter '933) in view of Hynes (EP 0 193 355; hereafter '355) or Gordon et al (4,457,933; hereafter '933) in view of Raffa et al (5,336,691; hereafter '691) or Gordon et al (4,457,933; hereafter '933) in view of Dudzinski (4,237,140; hereafter '140).

'933 also teaches opioid agonist and opioid antagonist composition and methods for treating pain. '933 does not teach inclusion of non-narcotic analgesics in the taught formulations.

'355, '691, and '140 are all relied upon for all that they teach as stated previously.

Art Unit: 1615

Accordingly, it would have been obvious to one skilled in the art at the time of the invention to include non-narcotic analgesics in the formulation of '933 in an effort to provide enhanced analgesia by means of producing analgesia though non-opioid antinociceptive pathways. Furthermore, since the interactions are synergistic, it would have been obvious to one skilled in the art at the time of the invention to use doses that would otherwise be subtherapeutic if given alone with the motivation of maintaining low instance of side effects while maintaining an analgesic dose.

4. Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Crain et al (5,512,578; hereafter '578) in combination with Hynes (EP 0 193 355; hereafter '355) and further in combination with Gauthier et al (5,552,422; hereafter '422) or Crain et al (5,512,578; hereafter '578) in combination with Raffa et al (5,336,691; hereafter '691) and further in combination with Gauthier et al (5,552,422; hereafter '422) or Crain et al (5,512,578; hereafter '578) in combination with Dudzinski (4,237,140; hereafter '140) and further in combination with Gauthier et al (5,552,422; hereafter '422).

'578, '355, '691, and '140 are all relied upon for all that they teach as stated previously. None of these references teaches inclusion of an additional non-opioid drug as required in instant claim 7.

'422 teaches combination of COX-2 inhibitors with acetaminophen and opioids (C 9, L 25-C 10, L 14).

Accordingly, it would have been obvious to one skilled in the art at the time of the invention to combine these teachings and include a COX-2 inhibitor in the above

Art Unit: 1615

obvious formulations to provide enhanced analgesia by means of producing analgesia though non-opioid and non-acetaminophen antinociceptive pathways.

5. Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Gordon et al (4,457,933; hereafter '933) in combination with Hynes (EP 0 193 355; hereafter '355) and further in combination with Gauthier et al (5,552,422; hereafter '422) or Gordon et al (4,457,933; hereafter '933) in combination with Raffa et al (5,336,691; hereafter '691) and further in combination with Gauthier et al (5,552,422; hereafter '422) or Gordon et al (4,457,933; hereafter '933) in combination with Dudzinski (4,237,140; hereafter '140) and further in combination with Gauthier et al (5,552,422; hereafter '422).

'933, '355, '691, and '140 are all relied upon for all that they teach as stated previously. None of these references teaches inclusion of an additional non-opioid drug as required in instant claim 7.

'422 teaches combination of COX-2 inhibitors with acetaminophen and opioids (C 9, L 25-C 10, L 14).

Accordingly, it would have been obvious to one skilled in the art at the time of the invention to combine these teachings and include a COX-2 inhibitor in the above obvious formulations to provide enhanced analgesia by means of producing analgesia though non-opioid and non-acetaminophen antinociceptive pathways.

6. Claims 11, 19-20, 27-31 and 35 are rejected under 35 U.S.C. 103(a) as being unpatentable over Crain et al (5,512,578; hereafter '578) in combination with Hynes (EP

Art Unit: 1615

. . .

0 193 355; hereafter '355) and further in combination with Oshlack et al (5,472,712; hereafter '712) or Crain et al (5,512,578; hereafter '578) in combination with Raffa et al (5,336,691; hereafter '691) and further in combination with Oshlack et al (5,472,712; hereafter '712) or Crain et al (5,512,578; hereafter '578) in combination with Dudzinski (4,237,140; hereafter '140) and further in combination with Oshlack et al (5,472,712; hereafter '712).

'578, '355, '691, and '140 are all relied upon for all that they teach as stated previously. None of these references controlled release formulations as required in the instant claims.

'712 teaches controlled release opioid formulations that meet the instant claims.

Accordingly, it would have been obvious to one skilled in the art at the time of the invention to provide controlled release formulations of the obvious previous compositions to reduce the frequency of administration.

7. Claims 11, 19-20, 27-31 and 35 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gordon et al (4,457,933; hereafter '933) in combination with Hynes (EP 0 193 355; hereafter '355) and further in combination with Oshlack et al (5,472,712; hereafter '712) or Gordon et al (4,457,933; hereafter '933) in combination with Raffa et al (5,336,691; hereafter '691) and further in combination with Oshlack et al (5,472,712; hereafter '712) or Gordon et al (4,457,933; hereafter '933) in combination with Dudzinski (4,237,140; hereafter '140) and further in combination with Oshlack et al (5,472,712; hereafter '712).



Art Unit: 1615

'933, '355, '691, and '140 are all relied upon for all that they teach as stated previously. None of these references controlled release formulations as required in the instant claims.

'712 teaches controlled release opioid formulations that meet the instant claims.

Accordingly, it would have been obvious to one skilled in the art at the time of the invention to provide controlled release formulations of the obvious previous compositions to reduce the frequency of administration.

Double Patenting

8. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321® may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

9. Claims 1-36 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-50 of U.S. Patent No. 6,277,384. Although the conflicting claims are not identical, they are not patentably distinct from each other because both are drawn to methods of use for oral

Art Unit: 1615

opioid agonist/antagonist compositions. Furthermore, the method of 6,277,384 discloses the compositions of the instant application.

10. Claims 1-36 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-36 of copending Application No. 09/503,020. Although the conflicting claims are not identical, they are not patentably distinct from each other because both are drawn to methods of use for oral opioid agonist/antagonist compositions. Furthermore, the method of Application No. 09/503,020 discloses the compositions of the instant application. This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Conclusion

11. Currently, no claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Todd D Ware whose telephone number is (703) 305-1700. The examiner can normally be reached on 8:30 AM - 6 PM, alternate Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K Page can be reached on (703)308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are (703) for regular communications and (703) for After Final communications.

Page 9

Application/Control Number: 09/992,936

Art Unit: 1615

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1234.

> Gollamudi S. Kishore, PhD Primary Examiner Group 1500

January 14, 2002